S&P 500   3,990.14 (+0.98%)
DOW   32,525.65 (+0.87%)
QQQ   308.65 (+0.88%)
AAPL   158.19 (+0.50%)
MSFT   274.77 (+0.93%)
META   201.75 (+1.99%)
GOOGL   102.04 (+0.81%)
AMZN   98.69 (+1.00%)
TSLA   188.49 (+2.86%)
NVDA   260.90 (+0.73%)
NIO   9.00 (+2.86%)
BABA   82.23 (+1.52%)
AMD   97.84 (+1.06%)
T   18.67 (+0.97%)
F   11.48 (+2.68%)
MU   58.96 (+2.29%)
CGC   1.92 (+3.23%)
GE   91.38 (+1.62%)
DIS   95.64 (+1.51%)
AMC   4.37 (+2.34%)
PFE   40.77 (-0.10%)
PYPL   74.53 (+1.80%)
NFLX   306.03 (+0.29%)
S&P 500   3,990.14 (+0.98%)
DOW   32,525.65 (+0.87%)
QQQ   308.65 (+0.88%)
AAPL   158.19 (+0.50%)
MSFT   274.77 (+0.93%)
META   201.75 (+1.99%)
GOOGL   102.04 (+0.81%)
AMZN   98.69 (+1.00%)
TSLA   188.49 (+2.86%)
NVDA   260.90 (+0.73%)
NIO   9.00 (+2.86%)
BABA   82.23 (+1.52%)
AMD   97.84 (+1.06%)
T   18.67 (+0.97%)
F   11.48 (+2.68%)
MU   58.96 (+2.29%)
CGC   1.92 (+3.23%)
GE   91.38 (+1.62%)
DIS   95.64 (+1.51%)
AMC   4.37 (+2.34%)
PFE   40.77 (-0.10%)
PYPL   74.53 (+1.80%)
NFLX   306.03 (+0.29%)
S&P 500   3,990.14 (+0.98%)
DOW   32,525.65 (+0.87%)
QQQ   308.65 (+0.88%)
AAPL   158.19 (+0.50%)
MSFT   274.77 (+0.93%)
META   201.75 (+1.99%)
GOOGL   102.04 (+0.81%)
AMZN   98.69 (+1.00%)
TSLA   188.49 (+2.86%)
NVDA   260.90 (+0.73%)
NIO   9.00 (+2.86%)
BABA   82.23 (+1.52%)
AMD   97.84 (+1.06%)
T   18.67 (+0.97%)
F   11.48 (+2.68%)
MU   58.96 (+2.29%)
CGC   1.92 (+3.23%)
GE   91.38 (+1.62%)
DIS   95.64 (+1.51%)
AMC   4.37 (+2.34%)
PFE   40.77 (-0.10%)
PYPL   74.53 (+1.80%)
NFLX   306.03 (+0.29%)
S&P 500   3,990.14 (+0.98%)
DOW   32,525.65 (+0.87%)
QQQ   308.65 (+0.88%)
AAPL   158.19 (+0.50%)
MSFT   274.77 (+0.93%)
META   201.75 (+1.99%)
GOOGL   102.04 (+0.81%)
AMZN   98.69 (+1.00%)
TSLA   188.49 (+2.86%)
NVDA   260.90 (+0.73%)
NIO   9.00 (+2.86%)
BABA   82.23 (+1.52%)
AMD   97.84 (+1.06%)
T   18.67 (+0.97%)
F   11.48 (+2.68%)
MU   58.96 (+2.29%)
CGC   1.92 (+3.23%)
GE   91.38 (+1.62%)
DIS   95.64 (+1.51%)
AMC   4.37 (+2.34%)
PFE   40.77 (-0.10%)
PYPL   74.53 (+1.80%)
NFLX   306.03 (+0.29%)
NASDAQ:PDEX

Pro-Dex - PDEX Stock Forecast, Price & News

$17.94
+0.23 (+1.30%)
(As of 03/21/2023 09:30 AM ET)
Add
Compare
Today's Range
$17.94
$17.94
50-Day Range
$15.29
$17.71
52-Week Range
$12.40
$21.43
Volume
113 shs
Average Volume
5,511 shs
Market Capitalization
$63.51 million
P/E Ratio
17.42
Dividend Yield
N/A
Price Target
$30.00

PDEX stock logo

About Pro-Dex (NASDAQ:PDEX) Stock

Pro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches. The company was founded on January 26, 1994 and is headquartered in Irvine, CA.

Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Stock News Headlines

StockNews.com Initiates Coverage on Pro-Dex (NASDAQ:PDEX)
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
Pro-Dex Is Growing But Expensive Given Its Risk
Why Pro-Dex, Inc. (NASDAQ:PDEX) Could Be Worth Watching
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
PDEX.A - | Stock Price & Latest News | Reuters
Pro-Dex, Inc. Announces Fiscal 2023 First Quarter Results
Pro-Dex Inc
See More Headlines
Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Company Calendar

Last Earnings
2/02/2023
Today
3/21/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDEX
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+69.4%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$3.86 million
Pretax Margin
10.38%

Debt

Sales & Book Value

Annual Sales
$42.04 million
Cash Flow
$1.31 per share
Book Value
$6.54 per share

Miscellaneous

Free Float
2,034,000
Market Cap
$62.69 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Richard Lee van Kirk
    President, Chief Executive Officer, COO & Director
  • Alisha K. CharltonAlisha K. Charlton
    Chief Financial Officer & Secretary













PDEX Stock - Frequently Asked Questions

What is Pro-Dex's stock price forecast for 2023?

0 Wall Street analysts have issued 12 month price objectives for Pro-Dex's shares. Their PDEX share price forecasts range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 69.4% from the stock's current price.
View analysts price targets for PDEX
or view top-rated stocks among Wall Street analysts.

How have PDEX shares performed in 2023?

Pro-Dex's stock was trading at $15.90 at the beginning of 2023. Since then, PDEX shares have increased by 11.4% and is now trading at $17.71.
View the best growth stocks for 2023 here
.

When is Pro-Dex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PDEX earnings forecast
.

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) posted its earnings results on Thursday, February, 2nd. The medical instruments supplier reported $0.24 earnings per share for the quarter. The medical instruments supplier earned $11.28 million during the quarter. Pro-Dex had a trailing twelve-month return on equity of 16.12% and a net margin of 8.64%.

What is Michael J. Berthelot's approval rating as Pro-Dex's CEO?

3 employees have rated Pro-Dex Chief Executive Officer Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH).

What is Pro-Dex's stock symbol?

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

Who are Pro-Dex's major shareholders?

Pro-Dex's stock is owned by a number of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (1.66%) and Advisor Group Holdings Inc. (0.47%). Insiders that own company stock include Alisha Charlton, Katrina Marie Kramer Philp, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III.
View institutional ownership trends
.

How do I buy shares of Pro-Dex?

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pro-Dex's stock price today?

One share of PDEX stock can currently be purchased for approximately $17.71.

How much money does Pro-Dex make?

Pro-Dex (NASDAQ:PDEX) has a market capitalization of $62.69 million and generates $42.04 million in revenue each year. The medical instruments supplier earns $3.86 million in net income (profit) each year or $1.03 on an earnings per share basis.

How many employees does Pro-Dex have?

The company employs 117 workers across the globe.

How can I contact Pro-Dex?

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for the company is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281.

This page (NASDAQ:PDEX) was last updated on 3/21/2023 by MarketBeat.com Staff